Opzelura (ruxolitinib)

pCPA File Number: 23007

Negotiation Status:

Active Negotiation

Indication(s):

Atopic dermatitis

Sponsor/Manufacturer:

Incyte Biosciences Canada Corporation

CDA-AMC Project Number:

SR0807-000

pCPA Engagement Letter Issued:

2026-02-25

Negotiation Process Concluded:

Not Applicable